Senti Biosciences logo

Senti BiosciencesNASDAQ: SNTI

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

26 May 2021

Next earnings report:

21 March 2025

Last dividends:

N/A

Next dividends:

N/A
$9.64 M
-96%vs. 3y high
17%vs. sector
-vs. 3y high
-vs. sector
-70%vs. 3y high
29%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 21:22:13 GMT
$2.10-$0.08(-3.67%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

SNTI Latest News

Senti Bio to Participate in Upcoming Investor Conferences
globenewswire.com03 September 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, including SENTI-202, a Logic Gated off-the-shelf CAR-NK investigational cell therapy in Phase 1 clinical trials, today announced its participation at the following investor conferences: H.C.

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
globenewswire.com13 August 2024 Sentiment: POSITIVE

– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML –

Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202
globenewswire.com05 August 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines (“CIRM”).

Senti Bio Announces Reverse Stock Split
globenewswire.com16 July 2024 Sentiment: NEGATIVE

Shares expected to begin trading on split-adjusted basis on July 18, 2024 Shares expected to begin trading on split-adjusted basis on July 18, 2024

Why Is Senti Biosciences (SNTI) Stock Up 32% Today?
investorplace.com25 June 2024 Sentiment: POSITIVE

Senti Biosciences (NASDAQ: SNTI ) stock is taking off on Tuesday alongside heavy pre-market trading of the preclinical biotechnology company's shares this morning. That has more than 8.5 million shares of SNTI stock changing hands as of this writing.

Senti Bio to Participate in Upcoming Conferences
GlobeNewsWire26 September 2023 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, today announced its participation at the following investor and healthcare industry conferences:

Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates
Zacks Investment Research11 August 2023 Sentiment: NEGATIVE

Senti Biosciences, Inc. (SNTI) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.86 per share a year ago.

Senti Bio to Participate in Upcoming Investor Conferences
GlobeNewsWire14 April 2023 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced its participation at the following investor conferences:

What type of business is Senti Biosciences?

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

What sector is Senti Biosciences in?

Senti Biosciences is in the Healthcare sector

What industry is Senti Biosciences in?

Senti Biosciences is in the Biotechnology industry

What country is Senti Biosciences from?

Senti Biosciences is headquartered in United States

When did Senti Biosciences go public?

Senti Biosciences initial public offering (IPO) was on 26 May 2021

What is Senti Biosciences website?

https://www.sentibio.com

Is Senti Biosciences in the S&P 500?

No, Senti Biosciences is not included in the S&P 500 index

Is Senti Biosciences in the NASDAQ 100?

No, Senti Biosciences is not included in the NASDAQ 100 index

Is Senti Biosciences in the Dow Jones?

No, Senti Biosciences is not included in the Dow Jones index

When was Senti Biosciences the previous earnings report?

No data

When does Senti Biosciences earnings report?

The next expected earnings date for Senti Biosciences is 21 March 2025